CARDIOGENIC SHOCK PROGRAM: BEYOND THE 'COLD AND WET' PHENOTYPE IN CARDIOGENIC SHOCK - PART A (CCC-216)

Friday, October 27, 2023

08:30 – 09:15 EST

Location: Palais, 513ABC

Target Audience: Critical care practitioners, Cardiac surgeons, Heart failure specialists

Chair(s)

Anique Ducharme, MD (she/her/hers)

Cardiologist
CCS, CCTN, CHFS, CANCARE
University of Montreal

Co-Chair(s)

Mena Gewarges

Cardiology Fellow
University of Toronto
University of Toronto
Anil Gupta

Cardiologist
Trillum Health Partners
Trillum Health Partners

Presenter(s)

Phyllis Billia, MD, PhD, FRCPC

Clinician Scientist
CCS, CCTN, CHFS, CANCARE
Toronto General Research Institute
Jacinthe Boulet (she/her/hers)

Advanced heart failure and transplantation
CHFS
Montreal Heart Institute
Darshan H. Brahmbhatt, MB BChir

Heart Failure Attending
ccs
University of Toronto
Andrew Caddell, MD, MSc, FRCPC

Cardiac Intensivist
CANCARE, CCTN
Dalhousie University
Stephanie Poon, MD, MSc, FRCPC

Cardiologist
CCS, CHFS
University of Toronto
JS

Janek Senaratne (he/him/his)

Cardiologist, Intensivist
ccs
University of Alberta

Panelist(s)

Faizan Amin, MD, FRCPC

Assistant Professor
CANCARE, CHFS, CCTN
McMaster University
MB

Mia Bertic, MD FRCP(C)

Cardiologist and Cardiac Intensivist
CANCARE
University of Toronto
Adriana Luk, MD, MSc, FRCPC (she/her/hers)

Critical Care Cardiologist, Advanced Heart Failure and Transplantation
University Health Network
University Health Network
DN

Dave Nagpal, MD

Cardiac Surgeon / Critical Care Physician
LHSC / UWO, TGLN, CANCARE, CCTN, CCS
Western University
Christopher Brian Overgaard, MD, MSc., FRCPC (he/him/his)

Director, Interventional and Complex PCI Program, Southlake Regional Healthcare Centre
ccs
CANCARE
Sean van Diepen, MD, MSc

Physician
University of Alberta
University of Alberta

Planning Committee Member(s)

Yoan Lamarche, ccs, cancare

Cardiac Surgeon/Intensivist
Cancare, cctn, chfs, ccs
Montreal Heart Institute
Gurmeet Singh, MD, MSc, FRCSC

Critical Care & Cardiac Surgery
CANCARE & CSCS
CANCARE, CSCS

Disclosure(s):

Mena Gewarges: No financial relationships to disclose

Phyllis Billia, MD, PhD, FRCPC: Abbott Laboratories: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Jacinthe Boulet: No financial relationships to disclose

Darshan H. Brahmbhatt, MB BChir: No financial relationships to disclose

Andrew Caddell, MD, MSc, FRCPC: No financial relationships to disclose

Janek Senaratne: No financial relationships to disclose

Faizan Amin, MD, FRCPC: No financial relationships to disclose

Gurmeet Singh, MD, MSc, FRCSC: Abbott Laboratories: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

identify the less common yet highly morbid cardiogenic shock phenotypes;
understand the complex pathophysiological processes in patients with cardiogenic shock; and
apply novel concepts in the management of patients with cardiogenic shock.

Session Description: While significant advances in the diagnosis and management of heart failure have been made in the last several decades, there continues to be an under-recognition of patients that present with cardiogenic shock. Cardiogenic shock is caused by severe impairment of cardiac performance that results in reduced cardiac output and end-organ hypoperfusion. Despite contemporary management of patients, the mortality remains high. Though a majority of patients present with LV failure with hypotension and end-organ malperfusion, a subset of CS patients exist which are more difficult to identify and treat.
This symposium is designed for those who care with patients with suspected cardiogenic shock, who may present differently. We present these less common subset of CS phenotypes with a clinical case, followed by an multidisciplinary faculty who will highlight clinical pearls in early recognition and management strategies. from the initial presentation in the field, or the emergency department, to the intensivists in specialized heart failure units.